News Novo Nordisk asks FDA not to allow GLP-1 compounding Novo Nordisk has asked the FDA to block compounders from making versions of its older, once-daily GLP-1 agonist liraglutide.
News Patient organisations 'too influenced by corporate funders' Researchers have called for action to safeguard the independence of patient advocacy organisations as they increasingly rely on pharma funding.
News Capricor files cell therapy for DMD cardiomyopathy with FDA Capricor completes its US filing for deramiocel, vying to become the first FDA-approved therapy for cardiomyopathy in Duchenne muscular dystrophy.
News Hutchmed cashes in a Chinese JV to help fund its pipeline Hutchmed has agreed to divest its share of a non-core Chinese JV through a pair of deals that will give it a cash injection to plough into R&D.
News First global approval for Daiichi Sankyo's Dato-DXd Daiichi Sankyo has claimed its first approval, in Japan, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan.
News Opdivo's subcutaneous PD-1 inhibitor cleared in US BMS beats MSD to the US subcutaneous PD-1 inhibitor market after Opdivo Qvantiq is cleared across nearly all the indications of the IV form.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
